Data / Drug companies / Time Cap Laboratories, Inc
Time Cap Laboratories, Inc: 87 products in the FDA NDC directory, labeler code 49483
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Time Cap Laboratories, Inc (labeler code 49483) lists 87 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 60 over the counter drugs, 27 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 14, 2026.
The request: Watch Time Cap Laboratories, Inc (FDA labeler code 49483): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 49483
- Products in commercial distribution
- 87
- Packages
- 216
- Finished drugs by generic name
- 38
- Prescription products
- 27
- Over the counter products
- 60
- Flagged as original packager
- 85 of 85 products that carry the flag
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- January 1, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 46 | 52.9% |
| Over the counter monograph drugs | 38 | 43.7% |
| Other unapproved drugs | 3 | 3.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 60 | 69% |
| Prescription drugs | 27 | 31% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Aspirin | 11 | 134 |
| Ibuprofen | 9 | 190 |
| Acetaminophen | 7 | 214 |
| Gabapentin | 3 | 91 |
| Metformin hcl | 3 | 13 |
| Guaifenesin | 3 | 123 |
| Sennosides | 3 | 65 |
| Fluoxetine hydrochloride | 3 | 44 |
| Naproxen | 3 | 58 |
| Paricalcitol | 3 | 13 |
| Nitroglycerin | 3 | 40 |
| Naproxen sodium | 2 | 100 |
| Metformin hydrochloride | 2 | 79 |
| Benzonatate | 2 | 42 |
| Diphenhydramine hydrochloride | 2 | 127 |
| Cetirizine hydrochloride | 2 | 119 |
| Valacyclovir hydrochloride | 2 | 28 |
| Sennosides and docusate sodium | 1 | 10 |
| Acetaminophen, aspirin and caffeine | 1 | 26 |
| Omeprazole 20mg | 1 | 2 |
| Acetaminophen, caffeine, and pyrilamine maleate | 1 | 7 |
| Acetaminophen 500mg/ diphenhydramine hcl 25mg | 1 | 1 |
| Bisacodyl | 1 | 60 |
| Acetaminophen tablet extended release | 1 | 3 |
| Phenylephrine hchloride | 1 | 1 |
| Ibuprofen capsules 200 mg | 1 | 3 |
| Loratadine | 1 | 125 |
| Caffeine | 1 | 38 |
| Famotidine | 1 | 138 |
| Guaifenesin dextromethorphan | 1 | 1 |
| Meclizine hcl | 1 | 32 |
| Ibupfrofen | 1 | 1 |
| Docusate sodium-sennosides | 1 | 1 |
| Acetaminophen, caffeine | 1 | 14 |
| Esomeprazole magnesium | 1 | 77 |
| Chlorpheniramine maleate | 1 | 31 |
| Acetaminophen, ibuprofen | 1 | 23 |
| Loratadine tablets usp, 10 mg | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 22 | 25.3% |
| Tablet | 22 | 25.3% |
| Capsule, liquid filled | 10 | 11.5% |
| Capsule | 9 | 10.3% |
| Tablet, delayed release | 7 | 8% |
| Tablet, coated | 6 | 6.9% |
| Tablet, extended release | 4 | 4.6% |
| Kit | 2 | 2.3% |
| Tablet, sugar coated | 2 | 2.3% |
| Tablet, chewable | 2 | 2.3% |
| Capsule, delayed release | 1 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Benzonatate 200 mg | 49483-947 | Capsule, liquid filled | Generic drugs (ANDA) | September 14, 2026 |
| Benzonatate 100 mg | 49483-946 | Capsule, liquid filled | Generic drugs (ANDA) | September 14, 2026 |
| Extra Strength Acetaminophen | 49483-673 | Tablet | Over the counter monograph drugs | June 1, 2026 |
| Omeprazole delayed release | 49483-731 | Tablet, delayed release | Generic drugs (ANDA) | December 15, 2025 |
| Loratadine 10 mg | 49483-732 | Tablet | Generic drugs (ANDA) | January 25, 2025 |
| Pain Reliever Dye Free | 49483-479 | Tablet | Over the counter monograph drugs | November 1, 2024 |
| Guaifenesin Extended Release 1200 mg | 49483-724 | Tablet | Generic drugs (ANDA) | January 8, 2024 |
| Guaifenesin Extended Release 600 mg | 49483-723 | Tablet | Generic drugs (ANDA) | January 8, 2024 |
| Esomeprazole magnesium | 49483-718 | Capsule, delayed release | Generic drugs (ANDA) | November 14, 2023 |
| Ibuprofen | 49483-700 | Capsule, liquid filled | Generic drugs (ANDA) | October 23, 2023 |
| Dual Action Pain Relief | 49483-716 | Tablet | Generic drugs (ANDA) | October 13, 2023 |
| Maximum strength Day cold and flu and Night severe cold and flu | 49483-726 | Kit | Over the counter monograph drugs | September 21, 2023 |
| Extra strength Acetaminophen PM | 49483-430 | Tablet | Over the counter monograph drugs | July 22, 2023 |
| Daytime cold and flu | 49483-693 | Capsule, liquid filled | Over the counter monograph drugs | July 6, 2023 |
| Maximum Strength Acid Reducer | 49483-720 | Tablet | Generic drugs (ANDA) | June 15, 2023 |
| Daytime Nighttime Cold and Flu | 49483-695 | Kit | Over the counter monograph drugs | June 7, 2023 |
| Muscle Aches and Pains Acetaminophen extended release | 49483-704 | Tablet, extended release | Generic drugs (ANDA) | November 7, 2022 |
| Cetirizine Hydrochloride | 49483-682 | Tablet | Generic drugs (ANDA) | May 30, 2022 |
| Fluoxetine | 49483-703 | Capsule | Generic drugs (ANDA) | February 12, 2022 |
| Fluoxetine | 49483-702 | Capsule | Generic drugs (ANDA) | February 12, 2022 |
| Fluoxetine | 49483-701 | Capsule | Generic drugs (ANDA) | February 12, 2022 |
| Cetirizine Hydrochloride Tablets,10 mg | 49483-692 | Tablet | Generic drugs (ANDA) | February 12, 2022 |
| Extra strength acetaminophen | 49483-697 | Tablet | Over the counter monograph drugs | February 11, 2022 |
| Acetaminophen | 49483-699 | Tablet, extended release | Generic drugs (ANDA) | October 4, 2021 |
| Ibuprofen | 49483-133 | Capsule, liquid filled | Generic drugs (ANDA) | July 27, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.